Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887470 · ClinicalTrials.gov registry record · Phase 2
2 Regimens of Lactulose for Colonoscopy Preparation in Adults
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT01887470: Completed Phase 2 study, sponsored by Cumberland Pharmaceuticals.
NCT01887470 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 55 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01887470, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of 2 regimens of lactulose as a preparation for colonoscopy.
Primary Outcome
Efficacy assessed by the physician's determination of the cleanliness of the colon using the cumulative Boston Bowel Preparation Scale (BBPS) score. The cumulative score is derived from three segmental scores assessed from the following three colonic segments: right colon, transverse colon, and left colon. Segment scores range from 0 to 3 with the following abbreviated definitions: 0=mucosa not visible; 1=a portion of the mucosa is visible; 2=minor residue, but mucosa is seen well; 3=entire muco
Interventions
- DRUG Full dose preparation
- DRUG Split dose preparation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01887470 record still lists
NCT01887470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Full dose preparation is the first listed.
NCT01887470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01887470 about?
NCT01887470 is a clinical study titled "2 Regimens of Lactulose for Colonoscopy Preparation in Adults". The purpose of the study is to determine the efficacy of 2 regimens of lactulose as a preparation for colonoscopy.
What is the current status of trial NCT01887470?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2013-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01887470?
The interventions under investigation include: Full dose preparation (DRUG), Split dose preparation (DRUG).
Who is sponsoring clinical trial NCT01887470?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01887470's enrollment target sits among peer trials
55 1153rd of 2000 higher than 841 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia